Apollo Endosurgery, Inc., a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. The company sells its products to medical services providers; and hospitals, outpatient surgical centers, clinics, and physicians in the United States, Brazil, Australia, and other European countries. Apollo Endosurgery, Inc. was founded in 2005 and is headquartered in Austin, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone512-279-5100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$60.85 million
Profitability
Miscellaneous
Employees215
Next Earnings Date8/14/2019 (Estimated)
OptionableNot Optionable
Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions
What is Apollo Endosurgery's stock symbol?
Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."
How were Apollo Endosurgery's earnings last quarter?
Apollo Endosurgery Inc (NASDAQ:APEN) issued its quarterly earnings results on Thursday, May, 2nd. The biotechnology company reported ($0.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.02. The biotechnology company earned $13.21 million during the quarter, compared to analysts' expectations of $13.21 million. Apollo Endosurgery had a negative return on equity of 97.89% and a negative net margin of 69.37%. View Apollo Endosurgery's Earnings History.
When is Apollo Endosurgery's next earnings date?
What price target have analysts set for APEN?
2 Wall Street analysts have issued 1 year target prices for Apollo Endosurgery's shares. Their predictions range from $3.00 to $4.00. On average, they anticipate Apollo Endosurgery's share price to reach $3.50 in the next year. This suggests that the stock has a possible downside of 0.8%. View Analyst Price Targets for Apollo Endosurgery.
What is the consensus analysts' recommendation for Apollo Endosurgery?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Apollo Endosurgery in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Apollo Endosurgery.
What are Wall Street analysts saying about Apollo Endosurgery stock?
Here are some recent quotes from research analysts about Apollo Endosurgery stock:
- 1. According to Zacks Investment Research, "Apollo Endosurgery, Inc. is engaged in designing and manufacturing of medical devices for weight loss solutions and gastrointestinal disorders. The Company's product segment includes ORBERA (R), LAP-BAND (R) and OverStitch(TM). The ORBERA is an Intragastric Balloon System which is a weight loss aid for adults suffering from obesity. The LAP-BAND System is developed for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables endoscopic surgery. It operates primarily in Asia Pacific, European Office, Latin and South America and Costa Rica. Apollo Endosurgery, Inc., formerly known as Lpath, Inc., is headquatered in Austin, Texas. " (5/8/2019)
- 2. Northland Securities analysts commented, "We are upgrading Perform rating. Our PT remains the same. The stock is down a lot from our original downgrade, and we think it is prudent to move to the sidelines. Our core concerns about the story, though, remain. Key Points Our updated outlook is based on the following: Business outlook remains weak. The company has already pre-announced Q4 revenue range of ~$15M (+/- a few hundred thousand), which was lower than consensus of ~$16M." (1/2/2019)
Has Apollo Endosurgery been receiving favorable news coverage?
Media stories about APEN stock have trended negative on Wednesday, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Apollo Endosurgery earned a daily sentiment score of -2.0 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the stock's share price in the immediate future.
Who are some of Apollo Endosurgery's key competitors?
Some companies that are related to Apollo Endosurgery include Westaim (WEDXF), Vapotherm (VAPO), Neuronetics (STIM), SeaSpine (SPNE), Pulse Biosciences (PLSE), Iradimed (IRMD), Cytosorbents (CTSO), Apyx Medical (APYX), Alphatec (ATEC), Liquidia Technologies (LQDA), Endologix (ELGX), T2 Biosystems (TTOO), iCAD (ICAD), Sensus Healthcare (SRTS) and RenovaCare (RCAR).
What other stocks do shareholders of Apollo Endosurgery own?
Who are Apollo Endosurgery's key executives?
Apollo Endosurgery's management team includes the folowing people:
- Mr. Todd Newton, CEO & Director (Age 56)
- Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
- Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
- Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
- Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner
Who are Apollo Endosurgery's major shareholders?
Apollo Endosurgery's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Gagnon Securities LLC (3.94%), NJ State Employees Deferred Compensation Plan (0.60%), Renaissance Technologies LLC (0.32%), Northern Trust Corp (0.12%) and Jacobs Levy Equity Management Inc. (0.08%). Company insiders that own Apollo Endosurgery stock include Bret Schwartzhoff, Holdings A/S Novo, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Institutional Ownership Trends for Apollo Endosurgery.
Which major investors are selling Apollo Endosurgery stock?
Which major investors are buying Apollo Endosurgery stock?
APEN stock was bought by a variety of institutional investors in the last quarter, including Jacobs Levy Equity Management Inc., Gagnon Securities LLC and NJ State Employees Deferred Compensation Plan. Company insiders that have bought Apollo Endosurgery stock in the last two years include Bret Schwartzhoff, Matthew S Crawford, Richard J Meelia, Sciences L P Ptv II, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Insider Buying and Selling for Apollo Endosurgery.
How do I buy shares of Apollo Endosurgery?
Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Apollo Endosurgery's stock price today?
One share of APEN stock can currently be purchased for approximately $3.53.
How big of a company is Apollo Endosurgery?
Apollo Endosurgery has a market capitalization of $77.38 million and generates $60.85 million in revenue each year. The biotechnology company earns $-45,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.
What is Apollo Endosurgery's official website?
How can I contact Apollo Endosurgery?
Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]
MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
